Selective NFAT targeting in T cells ameliorates GvHD while maintaining antitumor activity

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 4, 2015, Pages 1125-1130

  Vaeth, Martin ^a,c   Bäuerlein, Carina A ^b   Pusch, Tobias ^a   Findeis, Janina ^a   Chopra, Martin ^b,d   Mottok, Anja ^a,e   Rosenwald, Andreas ^a,b   Beilhack, Andreas ^a,b   Berberich Siebelt, Friederike ^a,b  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF AUCKLAND   (New Zealand)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Graft versus host disease; Graft versus leukemia effect; Hematopoietic stem cell transplantation; NFAT; Regulatory T cell

Indexed keywords

TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR NFAT1; TRANSCRIPTION FACTOR NFAT2; UNCLASSIFIED DRUG; CALCINEURIN INHIBITOR; CYCLOSPORIN; NFATC1 PROTEIN, MOUSE; NFATC2 PROTEIN, MOUSE; TACROLIMUS;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLUMINESCENCE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL INFILTRATION; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; TARGET ORGAN; ALLOGRAFT; ANIMAL; DISEASE MODEL; DRUG EFFECTS; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; KNOCKOUT MOUSE; PATHOLOGY;

ANIMALIA;

ALLOGRAFTS; ANIMALS; CALCINEURIN INHIBITORS; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CYCLOSPORINE; DISEASE MODELS, ANIMAL; GRAFT VS HOST DISEASE; GRAFT VS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MICE; MICE, KNOCKOUT; NFATC TRANSCRIPTION FACTORS; T-LYMPHOCYTES, REGULATORY; TACROLIMUS;

EID: 84921826195     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1409290112     Document Type: Article

References (38)

1. Ferrara JL, Levine JE, Reddy P, Holler E (2009) Graft-versus-host disease. Lancet 373(9674):1550-1561.
2. Jacobsohn DA, Vogelsang GB (2007) Acute graft versus host disease. Orphanet J Rare Dis 2:35.
3. Horowitz MM, et al. (1990) Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75(3):555-562.
4. Kolb HJ (2008) Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 112(12):4371-4383.
5. Toubert A, Glauzy S, Douay C, Clave E (2012) Thymus and immune reconstitution after allogeneic hematopoietic stem cell transplantation in humans: Never say never again. Tissue Antigens 79(2):83-89.
6. Warren EH, Deeg HJ (2013) Dissecting graft-versus-leukemia from graft-versus-hostdisease using novel strategies. Tissue Antigens 81(4):183-193.
7. Hogan WJ, Storb R (2004) Use of cyclosporine in hematopoietic cell transplantation. Transplant Proc 36(2, Suppl):367S-371S.
8. Hogan PG, Chen L, Nardone J, Rao A (2003) Transcriptional regulation by calcium, calcineurin, and NFAT. Genes Dev 17(18):2205-2232.
9. Müller MR, Rao A (2010) NFAT, immunity and cancer: A transcription factor comes of age. Nat Rev Immunol 10(9):645-656.
10. Serfling E, et al. (2000) The role of NF-AT transcription factors in T cell activation and differentiation. Biochim Biophys Acta 1498(1):1-18.
11. Bopp T, et al. (2005) NFATc2 and NFATc3 transcription factors play a crucial role in suppression of CD4+ T lymphocytes by CD4+ CD25+ regulatory T cells. J Exp Med 201(2):181-187.
12. Vaeth M, et al. (2012) Dependence on nuclear factor of activated T-cells (NFAT) levels discriminates conventional T cells from Foxp3+ regulatory T cells. Proc Natl Acad Sci USA 109(40):16258-16263.
13. Brunstein CG, et al. (2011) Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: Safety profile and detection kinetics. Blood 117(3):1061-1070.
14. Di Ianni M, et al. (2011) Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 117(14):3921-3928.
15. Edinger M, et al. (2003) CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 9(9):1144-1150.
16. Trenado A, et al. (2003) Recipient-type specific CD4+ CD25+ regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia. J Clin Invest 112(11):1688-1696.
17. Allan SE, et al. (2008) CD4+ T-regulatory cells: Toward therapy for human diseases. Immunol Rev 223:391-421.
18. Edinger M, Hoffmann P (2011) Regulatory T cells in stem cell transplantation: Strategies and first clinical experiences. Curr Opin Immunol 23(5):679-684.
19. Riley JL, June CH, Blazar BR (2009) Human T regulatory cell therapy: Take a billion or so and call me in the morning. Immunity 30(5):656-665.
20. Karwot R, Übel C, Bopp T, Schmitt E, Finotto S (2012) Increased immunosuppressive function of CD4(+)CD25(+)Foxp3(+)GITR+ T regulatory cells from NFATc2((-/-)) mice controls allergen-induced experimental asthma. Immunobiology 217(9):905-911.
21. Beilhack A, et al. (2005) In vivo analyses of early events in acute graft-versus-host disease reveal sequential infiltration of T-cell subsets. Blood 106(3):1113-1122.
22. Hippen KL, Riley JL, June CH, Blazar BR (2011) Clinical perspectives for regulatory T cells in transplantation tolerance. Semin Immunol 23(6):462-468.
23. Nguyen VH, et al. (2007) In vivo dynamics of regulatory T-cell trafficking and survival predict effective strategies to control graft-versus-host disease following allogeneic transplantation. Blood 109(6):2649-2656.
24. Chopra M, et al. (2013) Non-invasive bioluminescence imaging to monitor the immunological control of a plasmablastic lymphoma-like B cell neoplasia after hematopoietic cell transplantation. PLoS ONE 8(12):e81320.
25. Na IK, et al. (2010) Concurrent visualization of trafficking, expansion, and activation of T lymphocytes and T-cell precursors in vivo. Blood 116(11):e18-e25.
26. Serfling E, et al. (2012) NFATc1/αA: The other face of NFAT factors in lymphocytes. Cell Commun Signal 10(1):16.
27. Kaminski BA, et al. (2003) Reduced expression of NFAT-associated genes in UCB versus adult CD4+ T lymphocytes during primary stimulation. Blood 102(13):4608-4617.
28. Antin JH, Ferrara JL (1992) Cytokine dysregulation and acute graft-versus-host disease. Blood 80(12):2964-2968.
29. Truitt RL, Atasoylu AA (1991) Contribution of CD4+ and CD8+ T cells to graft-versushost disease and graft-versus-leukemia reactivity after transplantation of MHCcompatible bone marrow. Bone Marrow Transplant 8(1):51-58.
30. MacDonald KP, Shlomchik WD, Reddy P (2013) Biology of graft-versus-host responses: Recent insights. Biol Blood Marrow Transplant 19(1, Suppl):S10-S14.
31. + T cell-dependent antiviral immunity requires STIM1 and STIM2. J Clin Invest 124(10):4549-4563.
32. Weidinger C, Shaw PJ, Feske S (2013) STIM1 and STIM2-mediated Ca(2+) influx regulates antitumour immunity by CD8(+) T cells. EMBO Mol Med 5(9):1311-1321.
33. Vaeth M, et al. (2014) Follicular regulatory T cells control humoral autoimmunity via NFAT2-regulated CXCR5 expression. J Exp Med 211(3):545-561.
34. Zeiser R, et al. (2006) Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production. Blood 108(1):390-399.
35. Sieber M, Baumgrass R (2009) Novel inhibitors of the calcineurin/NFATc hub: Alternatives to CsA and FK506? Cell Commun Signal 7:25.
36. Bluestone JA (2011) The yin and yang of interleukin-2-mediated immunotherapy. N Engl J Med 365(22):2129-2131.
37. Koreth J, et al. (2011) Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med 365(22):2055-2066.
38. Matsuoka K, et al. (2013) Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci Transl Med 5(179): 179ra143.